PMID: 8615421May 1, 1996Paper

Trends in pharmacotherapy of Schizoaffective and bipolar affective disorders: a 5-year naturalistic study

The American Journal of Psychiatry
H H FennJ A Yesavage

Abstract

The authors' goal was to determine if the actual treatment of schizoaffective and bipolar affective disorders had changed in light of recent clinical drug trials that have suggested that valproate and carbamazepine may be equivalent in efficacy to lithium. Medication utilization rates for each 6-month period from July 1, 1989, to June 30, 1994, were compiled from the clinical database of the Palo Alto Veterans Affairs Medical Center. The use of valproate and valproate plus lithium was negligible in 1989. by 1994, these medication regimens accounted for 25% of the standard antimanic treatments used for bipolar affective disorder and 38% of the treatments used for schizoaffective disorder. Regimens of carbamazepine and carbamazepine plus lithium dropped from 24% of antimanic treatments in 1989 to 18% in 1994. From 1989 to 1994, there was a decline in the rate of lithium monotherapy for treatment of bipolar affective disorder (from 84% to 43%) and schizoaffective disorder (from 100% to 53%). In the past 5 years, valproate monotherapy has increased as a percentage of total antimanic pharmacotherapies, while lithium monotherapy has declined.

Citations

Oct 10, 1998·Psychiatry and Clinical Neurosciences·Y Y YangB H Wang
Mar 18, 2008·Journal of Affective Disorders·I WiltingE R Heerdink
Jan 30, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Masatake KuritaNorimichi Nakahata
Dec 1, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·Charles Bowden, Patrice Boyer
Dec 10, 2013·Journal of Affective Disorders·Farnaz HooshmandTerence A Ketter
Aug 21, 2007·Journal of Affective Disorders·Jon C Collins, Bentson H McFarland
Sep 17, 2003·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Fernando Madalena VolpeHumberto Correa
Mar 30, 2001·Journal of Psychopharmacology·Z Ahmed, I M Anderson
Jul 23, 2003·Journal of Psychopharmacology·Adrian J LloydAllan H Young
Dec 14, 2002·Bipolar Disorders·John R Geddes
May 16, 2007·Journal of Clinical Psychopharmacology·Leslie CitromeDavid W Boulton
May 25, 2012·European Archives of Psychiatry and Clinical Neuroscience·Konstantinos N FountoulakisEduard Vieta
Dec 7, 2007·The British Journal of Psychiatry : the Journal of Mental Science·Allan H Young, Judith M Hammond
Jun 5, 2001·The British Journal of Psychiatry : the Journal of Mental Science·J Geddes, G Goodwin
Dec 24, 2008·Expert Review of Neurotherapeutics·Leslie Citrome
Aug 19, 2014·Expert Review of Neurotherapeutics·Genevieve Curran, Arun Ravindran
Aug 3, 2017·European Archives of Psychiatry and Clinical Neuroscience·Katrin DruschkySermin Toto
Feb 24, 1998·Journal of Clinical Psychopharmacology·D A SolomonI W Miller
Dec 10, 2015·Journal of Clinical Psychopharmacology·Chia-Ming ChangHui-Ju Tsai
May 3, 2000·British Journal of Clinical Pharmacology·D B McLaughlinR G Dickinson
Apr 12, 2019·Clinical Practice and Epidemiology in Mental Health : CP & EMH·Gioia BaggianiAlberto Bocchetta
Aug 28, 2019·International Clinical Psychopharmacology·Laura CremaschiBernardo Dell'Osso

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Related Papers

The Journal of Clinical Psychiatry
E VietaGroup for the Study of Risperidone in Affective Disorders (GSRAD)
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
S L McElroy, P E Keck
© 2021 Meta ULC. All rights reserved